Beth Israel Deaconess Medical Center, Boston, MA [email protected]
Dr. Garnick reports receiving honoraria for being the editor-in-chief of the Harvard Medical School Annual Report on Prostate Diseases; receiving fees from Bayer HealthCare Pharmaceuticals for being a member of the data and safety monitoring board for a trial of radium-223 dichloride, and for being a medical reviewer for Health Dialog and Health Monitor publications; receiving fees for providing expert medical testimony on patent issues (for abiraterone and enzalutamide) and testosterone replacement and medical malpractice; receiving fees for being a member of both Food and Drug Association (FDA) Oncologic Drugs Advisory Committee panels as a special governmental employee and mock FDA panels related to products unrelated to this letter; and receiving stock grants for being a member of the scientific board of Dr. Consulta and Kalos Therapeutics. No other potential conflict of interest relevant to this letter was reported.
